ライフサイエンスコーパス: apnea

1 intervention for preventing CB-driven sleep apnea.

2 tions in their signaling could lead to sleep apnea.

3 pharmacologic therapy for obstructive sleep apnea.

4 rnate apnea type for obstructive and central apnea.

5 nates had aberrant respiration with frequent apnea.

6 rolled type 2 diabetes and obstructive sleep apnea.

7 children with more severe obstructive sleep apnea.

8 a decreases the drive to breathe and induces apnea.

9 for normal respiratory rhythm and preventing apnea.

10 actors and the presence of obstructive sleep apnea.

11 ssary for most patients with suspected sleep apnea.

12 Strikingly, the subjects were unaware of the apnea.

13 ellitus, hypertension, and obstructive sleep apnea.

14 ion fraction and predominantly central sleep apnea.

15 cians to use it prophylactically even before apnea.

16 ellitus, hypertension, and obstructive sleep apnea.

17 twork whose dysfunction contributes to sleep apnea.

18 increased gray matter with obstructive sleep apnea.

19 pack-years, systemic hypertension, and sleep apnea.

20 body (CB) activity may be a driver of sleep apnea.

21 itive consequences seen in obstructive sleep apnea.

22 a presymptomatic stage of obstructive sleep apnea.

23 ed HF patients with moderate-to-severe sleep apnea.

24 inspiratory frequency and inhibition causes apnea.

25 (H2S) as the major effector molecule driving apneas.

26 potential for reduction of obstructive sleep apneas.

27 observed in subjects with hypocapnia-related apneas.

28 hens perinatal respiratory drive and reduces apneas.

29 p, although not as remarkable as obstructive apneas.

30 d by severe bradycardia and life-threatening apneas.

31 x >/=25kg/m(2) (+1 point), obstructive sleep apnea (+1 point), gastroesophageal reflux (+1 point), an

32 .94 vs 2.80, P = .75), and obstructive sleep apnea (3.29 vs 2.83, P = .50).

33 om home (60.0% vs 33.5%; p < 0.001), 2) have apnea (34.3% vs 12.3%; p = 0.002), and 3) have seizures

34 6, vs 3; IQR, 2-5; P < .001), but less sleep apnea (578 [13.5%] vs 1264 [21.6%]; P < .001).

35 a prospective study of 74,543 cases of sleep apnea (60,125 outpatient, 14,418 inpatient) from the Swe

36 e were no differences in resolution of sleep apnea (62.6% vs 62.0%; P = .77), hypertension (47.1% vs

37 19.5%), dyslipidemia (14.0%-6.8%), and sleep apnea (9.6%-2.6%) was reduced.

38 prevalent condition and a hallmark of sleep apnea, a condition that has been associated with increas

39 ed HF patients with moderate-to-severe sleep apnea, adding ASV to OMT did not improve 6-month cardiov

40 to have increased odds of KCN included sleep apnea (adjusted OR, 1.13; 95% CI, 1.00-1.27; P = 0.05),

41 onia to a neonatal form of CMS with episodic apnea and a favorable prognosis when well managed at the

42 We found that the KO neonates showed severe apnea and altered respiratory pattern.

43 The association between sleep apnea and atrial fibrillation (AF) has not been examined

44 es the respiratory phenotype of PWS (central apnea and blunted response to respiratory challenges).

45 prolongs superior laryngeal C-fiber-mediated apnea and bradycardia through enhancing neuronal TRPV1 e

46 is capable of aggravating the SLCF-mediated apnea and bradycardia through TRPV1 sensitization and ne

47 s that PNE would aggravate the SLCF-mediated apnea and bradycardia via up-regulating TRPV1 expression

48 dence that addresses the links between sleep apnea and cardiovascular disease, and research that has

49 ical bases for considering obstructive sleep apnea and central sleep apnea associated with Cheyne-Sto

50 In older men, central apnea and Cheyne-Stokes respiration predicted increased

51 fibers (SLCFs) could induce bradycardia and apnea and has been implicated in SIDS pathogenesis, how

52 ), exhibit sleep apnea characterized by high apnea and hypopnea indices during rapid eye movement (RE

53 Similar high apnea and hypopnea indices were also noted in prehyperte

54 ctors included sleep disturbances (eg, sleep apnea and insomnia), mental health status (eg, posttraum

55 common sleep disorders of obstructive sleep apnea and insomnia.

56 We found that central apnea and O2 desaturation occurred when seizures spread

57 l stimulation of the amygdala reproduced the apnea and O2 desaturation.

58 re invasion of the amygdala co-occurred with apnea and oxygen desaturation, and electrical stimulatio

59 We evaluated associations between sleep apnea and receipt of a disability pension and mortality

60 ated CO and H2S signaling in the CB leads to apneas and suggest that CSE inhibition may be a useful t

61 en with moderate to severe obstructive sleep apnea, and also that even snoring alone affects neurocog

62 rom altitude sickness to airway obstruction, apnea, and atelectasis.

63 tension, dyslipidemia, depression, and sleep apnea, and changes in corresponding laboratory data were

64 ical symptoms of paroxysmal cough, whooping, apnea, and cyanosis.

65 tonia, optic nerve abnormalities, dysphagia, apnea, and early developmental arrest.

66 besity, diabetes mellitus, obstructive sleep apnea, and elevated blood pressure predispose to AF, and

67 patient-ventilator asynchrony, central sleep apnea, and glottic closure.

68 es mellitus, inflammation, obstructive sleep apnea, and others.

69 PDSA), which is considered more severe sleep apnea, and self-reported habitual snoring without PDSA (

70 besity, moderate-to-severe obstructive sleep apnea, and serum levels of C-reactive protein (CRP) grea

71 uency and regularity of ventilation, reduces apneas, and protects against hypoxia-induced respiratory

72 y control system is compromised (e.g., sleep apnea, apnea of prematurity, spinal injury, or motor neu

73 nsist mainly obstructive, central, and mixed apnea, as well as hypopneas.

74 ng obstructive sleep apnea and central sleep apnea associated with Cheyne-Stokes respiration as poten

75 Central sleep apnea associated with Cheyne-Stokes respiration predicts

76 prevalence of obstructive and central sleep apnea associated with Cheyne-Stokes respiration.

77 s with IgE-mediated food allergy, reports of apnea attack associated with IgE-mediated food allergy a

78 Central apnea attack might be occurred in patient with IgE-media

79 with IgE-mediated wheat allergy experienced apnea attack with strong desaturation after an immediate

80 Among patients with obstructive sleep apnea, both CPAP and MADs were associated with reduction

81 rovoked, cortical seizures frequently led to apneas, brainstem SD, cardiorespiratory failure, and dea

82 ion fraction and predominantly central sleep apnea, but all-cause and cardiovascular mortality were b

83 symptomatic patients with obstructive sleep apnea, but its effectiveness has not been evaluated acro

84 iratory pattern and are important for reflex apneas, but that the rhythm can persist after substantia

85 oninvasive ventilator to treat central sleep apnea by delivering servo-controlled inspiratory pressur

86 sive mechanical ventilation to treat central apnea (CA) occurring at night ("sleep apnea") in patient

87 ypertension, diabetes, and obstructive sleep apnea can reduce atrial fibrillation episodes.

88 pans diabetes, renal disease, obesity, sleep apnea, cardiovascular disease, and cognitive disorders,

89 RATIONALE: Obstructive sleep apnea causes intermittent hypoxemia, hemodynamic fluctua

90 indices: apnea-hypopnea index, central sleep apnea (central apnea index, >/=5 vs. <5), central sleep

91 molecule carbon monoxide (CO), exhibit sleep apnea characterized by high apnea and hypopnea indices d

92 Central apnea, Cheyne-Stokes respiration, and sleep-disordered b

93 x, higher body mass index, concomitant sleep apnea, conversion to laparotomy, longer operation time,

94 Central sleep apnea (CSA) is a highly prevalent, though often unrecogn

95 f medical comorbidities (hypertension, sleep apnea, diabetes, and hyperlipidemia), functional status,

96 nd AMPK-alpha2 exhibited hypoventilation and apnea during hypoxia, with the primary precipitant being

97 ously breathing patients to induce sustained apnea during PET/CT.

98 increase in the number of central and mixed apneas during the follow-up, although not as remarkable

99 king brain damage and/or sudden death due to apnea episodes and cardiorespiratory failure.

100 of an anticholinergic bronchodilator reduced apnea episodes in global and cholinergic CPEB2-KO mice.

101 s, chronic kidney disease, obstructive sleep apnea, etc.

102 K expression precipitate hypoventilation and apnea, even when carotid body afferent input is normal.

103 participants were completely unaware of the apnea evoked by stimulation and expressed no dyspnea, de

104 pendent activation of RTN neurons, increased apnea frequency, and blunted ventilatory responses to CO

105 with developments in the treatment of sleep apnea, have accumulated in recent years.

106 increased pulse pressure, obstructive sleep apnea, high-level physical training, diastolic dysfuncti

107 ors that included obesity, obstructive sleep apnea, higher comorbidity, and use of prescription opioi

108 us mean diffusivity correlated with a higher apnea hypopnea index (Spearman's r = -0.50, p = 0.008) a

109 saturation (SaO2); right putamen tCho/Cr and apnea hypopnea index; right putamen GABA/Cr and baseline

110 ion sites in patients with obstructive sleep apnea hypopnea syndrome (OSAHS).

111 SDB was characterized by apnea-hypopnea index >/=15 events per hour (polysomnogra

112 ients with newly revascularized CAD and OSA (apnea-hypopnea index >/=15/h) without daytime sleepiness

113 with paroxysmal AF (43 with >/=moderate OSA [apnea-hypopnea index >/=15] and 43 without OSA [apnea-hy

114 ea-hypopnea index >/=15] and 43 without OSA [apnea-hypopnea index <5]), right atrial and left atrial

115 of portable monitors, or association between apnea-hypopnea index (AHI) and health outcomes among com

116 risk for all-cause mortality, with FEV1 and apnea-hypopnea index (AHI) as the primary exposure indic

117 moderate to severe SDB, defined as having an Apnea-Hypopnea Index (AHI) greater than 15 as assessed b

118 In fully adjusted models, patients with apnea-hypopnea index (AHI) greater than 30 had a 30% hig

119 week, on a nondialysis day, subjects with an apnea-hypopnea index (AHI) greater than or equal to 20 h

120 revalence of periodontal disease between the apnea-hypopnea index (AHI) groups, with a negligible Spe

121 Women with an apnea-hypopnea index (AHI) less than 10 comprised the co

122 ricular ejection fraction of 45% or less, an apnea-hypopnea index (AHI) of 15 or more events (occurre

123 r, OAs have variable success at reducing the apnea-hypopnea index (AHI), and predicting responders is

124 Our main exposures were the obstructive apnea-hypopnea index (AHI), central apnea index (CAI >/=

125 ed into four severity groups on the basis of apnea-hypopnea index (AHI), followed by comparisons of c

126 OSA severity was defined by the apnea-hypopnea index (AHI): severe >30, moderate >15-30,

127 al apnea (OR, 6.31; 95% CI, 1.94-20.51), and apnea-hypopnea index (OR, 1.22; 95% CI, 1.08-1.39 [per 5

128 associated with significant improvements in apnea-hypopnea index (P < 0.001); microarousal index (P

129 surgical responses (>/=50% reduction in the apnea-hypopnea index [AHI] and <10 events/hour) in patie

130 participants were identified as free of OSA (apnea-hypopnea index [AHI] of <5 events/h and not treate

131 A total of 25 adults with positional OSAS (apnea-hypopnea index [AHI]supine:AHInon-supine >/= 2) we

132 Mean number of events measured by the apnea-hypopnea index decreased from 35.7/h to 2.1/h at 6

133 M and non-REM sleep was quantified using the apnea-hypopnea index in REM (AHIREM) and non-REM sleep (

134 Participants with an apnea-hypopnea index of 15 to 50 events per hour were ra

135 leep-disordered breathing was ascertained by apnea-hypopnea index or clinical diagnosis.

136 bjects (1,839 in fully adjusted models), the apnea-hypopnea index was used to classify OSA as none (0

137 women diagnosed with moderate to severe OSA (apnea-hypopnea index, >/=15) in 19 Spanish sleep units.

138 Seventy-one subjects (ages, 55-76 yr; apnea-hypopnea index, 0.2-96.6 events/h) were evaluated

139 ge, 54 [10] yr; median [interquartile range] apnea-hypopnea index, 41 [35-53]; mean [SD] Epworth slee

140 ea or Cheyne-Stokes respiration, obstructive apnea-hypopnea index, and percentage of sleep time with

141 rs11691765, GPR83, P = 1.90 x 10(-8) for the apnea-hypopnea index, and rs35424364; C6ORF183/CCDC162P,

142 en saturation as measured by pulse oximetry, apnea-hypopnea index, and the fraction of events that we

143 s were metaanalyzed for association with the apnea-hypopnea index, average oxygen saturation during s

144 ion was assessed for baseline sleep indices: apnea-hypopnea index, central sleep apnea (central apnea

145 studies focused on traits defined using the apnea-hypopnea index, which contains limited information

146 However, apnea/hypopnea incidence was similarly increased in both

147 p was divided into 3 sub-groups based on the apnea/hypopnea index (AHI): mild, moderate, or severe OS

148 The 24-h prevalence of predominant CAs (apnea/hypopnea index [AHI] >/=5 events/h, with CA of >50

149 active expiration, ultimately progressing to apnea, i.e., cessation of both inspiration and active ex

150 ase, diabetes mellitus, or obstructive sleep apnea (ie, lone AF) undergoing ablation and 25 matched c

151 rventilation, hypocapnia was associated with apnea in 3 cases and ventilation persisted in 7 cases (3

152 e in the genioglossus of patients with sleep apnea in comparison with obese normal subjects with [(18

153 channel, non-selective (Nalcn) causes lethal apnea in humans and mice, we investigated Nalcn function

154 nergic neurons sufficiently caused increased apnea in neonatal pups and airway hyper-reactivity in ad

155 atory illness (including suspected sepsis or apnea in neonates) were enrolled from 1 January 2015 to

156 Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure) trial results.

157 d soon after birth; surviving mice developed apneas in adulthood.

158 on of CSE with l-propargyl glycine prevented apneas in both HO-2(-/-) mice and SH rats.

159 of SERT activity is sufficient to cause the apneas in Necdin-KO pups, and that fluoxetine may offer

160 entral apnea (CA) occurring at night ("sleep apnea") in patients with systolic heart failure (HF) hav

161 tructive apnea-hypopnea index (AHI), central apnea index (CAI >/= 5), and Cheyne-Stokes breathing.

162 and 5.3, respectively; all p < 0.05; central apnea index [CAI] of </>/=10 events/h; log-rank 8.9, 11.

163 evations in the obstructive or central sleep apnea index or the presence of Cheyne-Stokes breathing a

164 hypopnea index, central sleep apnea (central apnea index, >/=5 vs. <5), central sleep apnea or Cheyne

165 Obstructive sleep apnea is a common disorder associated with increased ris

166 Sleep apnea is a common problem affecting daily functioning an

167 Obstructive sleep apnea is a state-dependent disease.

168 Obstructive sleep apnea is associated with considerable health risks.

169 Obstructive sleep apnea is associated with higher levels of blood pressure

170 al research indicates that obstructive sleep apnea is associated with increases in the incidence and

171 Central sleep apnea is associated with poor prognosis and death in pat

172 Sleep apnea is common in hospitalized heart failure (HF) patie

173 Sleep apnea is highly prevalent in patients with cardiovascula

174 circuitry that mediates arousal during sleep apnea is not known.

175 In conclusion, inpatient sleep apnea is related to a higher risk of disability pension

176 The key to tolerate such extensive apnea is the dive response, which comprises bradycardia

177 tic factors in influencing obstructive sleep apnea, its genetic basis is still largely unknown.

178 Prolonged photostimulation produced apneas lasting as long as the light pulse.

179 0) typically found with hypoxia during sleep apnea, M94I resulted in 37% reduction in peak INa compar

180 Relative to subjects without apnea, moderate-to-severe OSA was significantly associat

181 ion of the peak wave compared to baseline or apnea, no wave for 10 seconds) (Study group, n = 55), or

182 as the prevalence of predominant obstructive apneas (OA) was 12.8% (AHI >/=5 events/h with OAs >50%;

183 tion, hypertension, diabetes mellitus, sleep apnea, obesity, excessive alcohol, smoking, hyperthyroid

184 tors (hypertension, diabetes mellitus, sleep apnea, obesity, excessive alcohol, smoking, hyperthyroid

185 Apnea occurred more than hypopnea (p < 0.0001).

186 Central sleep apnea (odds ratio [OR], 2.58; 95% confidence interval [C

187 the most significant risk factors were sleep apnea (odds ratio [OR], 3.80; 95% CI, 1.00-14.49; P = .0

188 Caffeine therapy for apnea of prematurity did not significantly reduce the co

189 Advantages of caffeine for apnea of prematurity have prompted clinicians to use it

190 Caffeine citrate therapy for apnea of prematurity reduces the rates of bronchopulmona

191 randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between October 11, 1999, and

192 ne citrate or placebo until drug therapy for apnea of prematurity was no longer needed.

193 Children enrolled in the CAP (Caffeine for Apnea of Prematurity) randomized controlled trial and as

194 ol system is compromised (e.g., sleep apnea, apnea of prematurity, spinal injury, or motor neuron dis

195 Apnea of prematurity, which is prevalent among infants b

196 ut the effects of treating obstructive sleep apnea on glycemic control in patients with type 2 diabet

197 ate, refer patients for evaluation for sleep apnea or asthma.

198 ted with adverse events, including fever and apnea or bradycardia, in the immediate postimmunization

199 ral apnea index, >/=5 vs. <5), central sleep apnea or Cheyne-Stokes respiration, obstructive apnea-hy

200 x (AHI) of 15 or more events (occurrences of apnea or hypopnea) per hour, and a predominance of centr

201 .27; 95% CI, 1.13-4.56), but not obstructive apnea or hypoxemia, predicted incident atrial fibrillati

202 Cheyne-Stokes respiration with central sleep apnea (OR, 2.27; 95% CI, 1.13-4.56), but not obstructive

203 .50), Cheyne-Stokes respiration with central apnea (OR, 6.31; 95% CI, 1.94-20.51), and apnea-hypopnea

204 , atrial fibrillation was related to central apnea (OR, 9.97; 95% CI, 2.72-36.50), Cheyne-Stokes resp

205 following: CHA2DS2-VASc score of >/=2, sleep apnea, or body mass index >30 kg/m(2).

206 ycemic control, those with more severe sleep apnea, or those who were adherent to therapy.

207 chological issues, asthma, obstructive sleep apnea, orthopedic problems, and adverse cardiovascular a

208 overload, both obstructive and central sleep apnea (OSA and CSA) are common.

209 Obstructive sleep apnea (OSA) affects 8-10% of the population, is characte

210 ng the association between obstructive sleep apnea (OSA) and Alzheimer's disease is OSA leading to de

211 Obstructive sleep apnea (OSA) and nocturnal hypoxemia are associated with

212 Risk factors for obstructive sleep apnea (OSA) and the development of subsequent cardiovasc

213 Treatment is needed for obstructive sleep apnea (OSA) because untreated OSA can result in serious

214 Surgical success for obstructive sleep apnea (OSA) depends on identifying sites of obstruction

215 between periodontitis and obstructive sleep apnea (OSA) has been suggested.

216 An adverse role for obstructive sleep apnea (OSA) in cancer epidemiology and outcomes has rece

217 s, estimated prevalence of obstructive sleep apnea (OSA) in the United States is 10% for mild OSA and

218 Mild obstructive sleep apnea (OSA) is a highly prevalent disorder in adults; ho

219 Obstructive sleep apnea (OSA) is a known risk factor for atherosclerosis.

220 Obstructive sleep apnea (OSA) is a risk factor for type 2 diabetes that ad

221 Obstructive sleep apnea (OSA) is a sleep disorder characterized by disrupt

222 Obstructive sleep apnea (OSA) is a worldwide disease whose prevalence is i

223 Obstructive sleep apnea (OSA) is associated with atrial remodeling, atrial

224 Although obstructive sleep apnea (OSA) is associated with impaired glucose toleranc

225 RATIONALE: Obstructive sleep apnea (OSA) is associated with several pathophysiologica

226 Obstructive sleep apnea (OSA) is characterized by recurrent upper airway o

227 Obstructive sleep apnea (OSA) is common in patients with coronary artery d

228 Obstructive sleep apnea (OSA) is common in people with hypertension, parti

229 Obstructive sleep apnea (OSA) is more common among patients with asthma; w

230 raphy (PSG) for diagnosing obstructive sleep apnea (OSA) is unclear.

231 ite emerging evidence that obstructive sleep apnea (OSA) may cause metabolic disturbances independent

232 The effect of obstructive sleep apnea (OSA) syndrome in the peripapillary retinal nerve

233 reased risk for developing obstructive sleep apnea (OSA), and both of these conditions are associated

234 tant hypertension (RH) and obstructive sleep apnea (OSA), the blood pressure response to continuous p

235 floppy eyelid syndrome and obstructive sleep apnea (OSA), the diagnostic criteria of floppy eyelid sy

236 tcomes are associated with obstructive sleep apnea (OSA).

237 pressure for patients with obstructive sleep apnea (OSA).

238 ith high and low risks for obstructive sleep apnea (OSA).

239 patients with symptomatic obstructive sleep apnea (OSA).

240 common treatment used for obstructive sleep apnea (OSA).

241 linked to the severity of obstructive sleep apnea (OSA).

242 aliber and the severity of obstructive sleep apnea (OSA).

243 tical pathology underlying obstructive sleep apnea (OSA).

244 proportion of PRN(+) case-patients reported apnea (P = .005).

245 rovement in ACT scores was obstructive sleep apnea (P = 0.016).

246 several traits involved in obstructive sleep apnea pathogenesis and may be a therapeutic target; howe

247 he associations of physician-diagnosed sleep apnea (PDSA), which is considered more severe sleep apne

248 the screening accuracy of the multivariable apnea prediction score followed by home portable monitor

249 During persistent apneas, prolonged photoinhibition restored rhythmic brea

250 of men and 21% of women with inpatient sleep apnea received a disability pension.

251 PFV-induced apnea reduces thoracic organ motion and increases lesion

252 cant findings reported for obstructive sleep apnea-related physiologic traits in any population.

253 isorders including obstructive sleep apnoea (apnea), REM sleep behaviour disorder (RBD) and narcoleps

254 well as a significantly higher rate of sleep apnea remission (72.5% vs 49.3%, P < .001) and higher sa

255 .5, 99% confidence interval (CI): 1.5, 1.6), apnea (RR = 5.8, 99% CI: 5.1, 6.5), asphyxia (RR = 8.5,

256 ilirubinemia, respiratory distress syndrome, apnea, sepsis, anemia, transient tachypnea of the newbor

257 acteristics and markers of obstructive sleep apnea severity (hypoxemia, respiratory disturbances, and

258 stigate whether markers of obstructive sleep apnea severity are associated with gray matter changes a

259 emature infants after caffeine treatment for apnea suggests that caffeine may protect against ROP.

260 in patients with intermediate-to-high sleep apnea suspicion (most patients requiring a sleep study).

261 Sequentially screened patients with sleep apnea suspicion were randomized to respiratory polygraph

262 he Epworth Sleepiness Scale (ESS), the Sleep Apnea Symptoms Questionnaire (SASQ), continuous positive

263 The prevalence of obstructive sleep apnea syndrome (OSAS) in patients with nonarteritic ante

264 Obstructive sleep apnea syndrome (OSAS) is associated with intermittent hy

265 Obstructive sleep apnea syndrome (OSAS) leads to neurocognitive and autono

266 te the correlation between obstructive sleep apnea syndrome (OSAS) risk with periodontal disease and

267 patients with concomitant obstructive sleep apnea syndrome (OSAS) seems to have a favorable impact o

268 s-dependent cognition, and obstructive sleep apnea syndrome (OSAS).

269 le in treating snoring and obstructive sleep apnea syndrome (OSAS).

270 significant prevalence of obstructive sleep apnea syndrome in patients in waiting list for LT, and L

271 Obstructive sleep apnea syndrome is a highly prevalent disease resulting i

272 Prevalence of obstructive sleep apnea syndrome was 38% before the LT, 86% at 6 months, a

273 ody mass index [BMI] >35), obstructive sleep apnea syndrome, or other causes of respiratory failure.

274 cs with moderate to severe obstructive sleep apnea syndrome.

275 ails of the clinical examination, details of apnea testing, and details of ancillary testing.

276 all aspects of the clinical examination and apnea testing, and specifying appropriate ancillary test

277 s review, we discuss the mechanisms of sleep apnea, the evidence that addresses the links between sle

278 rder to assess the respiratory status during apnea, the mechanical ventilator was paused for up to 2

279 s detected after the incorporation of infant apnea to the 2014 case definition.

280 earch that has addressed the effect of sleep apnea treatment on cardiovascular disease and clinical e

281 y, we review the recent development in sleep apnea treatment options, with special consideration of t

282 lesterol, cardiac medications, and alternate apnea type for obstructive and central apnea.

283 ocardial ischemia and periods of respiratory apnea using a readily available mobile platform.

284 Prevalence of severe obstructive sleep apnea was 51% (95% confidence interval, 34-69) in patien

285 Outpatient sleep apnea was associated with a higher risk of receiving a d

286 PDSA, a marker of more severe sleep apnea, was associated with higher risk of incident AF in

287 ay underlie cardiovascular sequelae of sleep apnea, we evaluated the effects of nocturnal supplementa

288 betes, hypertension, dyslipidemia, and sleep apnea were found to be significantly associated with ban

289 screened patients with OHS with severe sleep apnea were randomized into the above-mentioned groups fo

290 talized with HF and moderate-to-severe sleep apnea were randomized to ASV plus optimized medical ther

291 ol) on BP in patients with obstructive sleep apnea were selected by consensus.

292 Sleep apnea, which is the periodic cessation of breathing duri

293 here were no associations of inpatient sleep apnea with cancer mortality.

294 evidence that treatment of obstructive sleep apnea with continuous positive airway pressure improves

295 dence supports a causal association of sleep apnea with the incidence and morbidity of hypertension,

296 t 47 +/- 7 min afterward, during PFV-induced apnea (with imaging lasting >/=8.5 min).

297 d no previous diagnosis of obstructive sleep apnea, with a glycated hemoglobin level of 6.5-8.5%, and

298 ithout PDSA (HS), a surrogate for mild sleep apnea, with incident AF in white, black, and Hispanic pa

299 the RR and TV estimation algorithms detected apnea within 7.9 +/- 1.1 sec and 5.5 +/- 2.2 sec, respec

300 nd that fluid removal by UF attenuates sleep apnea without altering uremic status.